Climb Bio to Be Added to the Nasdaq Biotechnology Index

GlobeNewswireDec 19, 2024 07:00 ET

Leerink Partners Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $10

Moomoo NewsDec 2, 2024 12:32 ET · Ratings

Express News | Climb Bio Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $10

ReutersDec 2, 2024 06:28 ET

Eliem Therapeutics GAAP EPS of -$0.13

Seeking AlphaNov 14, 2024 12:45 ET

Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases

TipRanksNov 13, 2024 23:40 ET

Express News | Climb Bio Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing

ReutersNov 12, 2024 16:52 ET